If you've seen the corporate presentation, you know what I'm talking about.
This is what's due Q4 2005:
-Meet with FDA regarding Nimotuzumab / approval for Phase III in US with Nimotuzumab (?) � European approval of pivotal Phase III trial- children � Stomach cancer trial IND approval with Tesmilifene � Initiate NSCLC trial � patients unfit for chemotherapy � Initiate Taxotere/Tesmilifene trial metastatic breast cancer
BTW, look at SLIDE 14: YMI put in a slide about Merck and Takeda's partnership re Matuzumab and financials. Why? Has nothing to do with the overall YMI corp presentation. My take: they are sending the subliminal message that there will be a substantial partnership(s) for Nimotuzumab. And why not...
I know, I know. If they do deliver on their promises, I will be pleased.
I have to admit I am frustrated because this company is so great--why the hell are we still at ~$3.00? I see total POS companies with a single product in stage 2 that are worth 3 to 5 times YMI.
Regarding slide 14: Have you had a chance to listen to the R&R Conference? Allan's commentary on the Merck/Takeda slide was not-too-subliminal. Let's hope there is something similar in the cards for YMI. Soon would be nice.
Just needed to vent, anyway. Part of my problem is that I was growing used to big returns in a few months--it's been a very good two years for my biotech portfolio. Now I just need to relearn patience.